Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas

[1]  A. Olshen,et al.  Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering , 2020, Genome Medicine.

[2]  S. Hewitt,et al.  Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients , 2020, Journal of translational medicine.

[3]  Dan Xu,et al.  Identification of a novel cancer stem cell subpopulation that promotes progression of human fatal renal cell carcinoma by single-cell RNA-seq analysis , 2020, International journal of biological sciences.

[4]  Leiming Wang,et al.  A novel isocitrate dehydrogenase 1 G131D mutation in glioblastoma , 2020, Chinese medical journal.

[5]  Erin L. Schenk,et al.  Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing , 2020, Cell.

[6]  R. Derynck,et al.  TGFβ biology in cancer progression and immunotherapy , 2020, Nature Reviews Clinical Oncology.

[7]  Lihua Zhang,et al.  Inference and analysis of cell-cell communication using CellChat , 2020, Nature Communications.

[8]  Zemin Zhang,et al.  The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications , 2020, Cellular & Molecular Immunology.

[9]  Yuan Zhang,et al.  Single cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. , 2020, Journal of hepatology.

[10]  Ye Wang,et al.  Changing Technologies of RNA Sequencing and Their Applications in Clinical Oncology , 2020, Frontiers in Oncology.

[11]  A. Flanagan,et al.  Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma , 2020, The journal of pathology. Clinical research.

[12]  Wei Huang,et al.  The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma. , 2019, Neurosurgery.

[13]  J. Zhao,et al.  STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway , 2019, Cancer science.

[14]  J. Herman,et al.  Epigenetic heterogeneity in cancer , 2019, Biomarker Research.

[15]  S. Batra,et al.  PTTG1: a Unique Regulator of Stem/Cancer Stem Cells in the Ovary and Ovarian Cancer , 2019, Stem Cell Reviews and Reports.

[16]  Mariella G. Filbin,et al.  An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma , 2019, Cell.

[17]  F. Şahin,et al.  Distinctive role of dysregulated miRNAs in chordoma cancer stem‐like cell maintenance , 2019, Experimental cell research.

[18]  M. Toda,et al.  Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma , 2019, Journal of Neuro-Oncology.

[19]  L. Yao,et al.  Application of nomograms to predict overall and cancer-specific survival in patients with chordoma , 2019, Journal of bone oncology.

[20]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[21]  J. Steiner,et al.  Mucosal expression of S100A12 (calgranulin C) and S100A8/A9 (calprotectin) and correlation with serum and fecal concentrations in dogs with chronic inflammatory enteropathy. , 2019, Veterinary immunology and immunopathology.

[22]  Liming Cheng,et al.  Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review , 2019, Front. Oncol..

[23]  Z. Duan,et al.  Advances in immune checkpoint inhibitors for bone sarcoma therapy , 2019, Journal of bone oncology.

[24]  A. Butte,et al.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.

[25]  Feng Li,et al.  CellMarker: a manually curated resource of cell markers in human and mouse , 2018, Nucleic Acids Res..

[26]  S. Potter,et al.  Single-cell RNA sequencing for the study of development, physiology and disease , 2018, Nature Reviews Nephrology.

[27]  Wei Huang,et al.  Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor. , 2018, Neurosurgery.

[28]  C. Hedrich,et al.  TCRαβ+CD3+CD4-CD8- (double negative) T cells in autoimmunity. , 2018, Autoimmunity reviews.

[29]  M. Plomann,et al.  TGFB1 is secreted through an unconventional pathway dependent on the autophagic machinery and cytoskeletal regulators , 2018, Autophagy.

[30]  M. Tan,et al.  Interleukin‐6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression , 2018, Cancer science.

[31]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[32]  Wei Huang,et al.  Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients , 2018, Cancer Immunology, Immunotherapy.

[33]  A. Hinck,et al.  TGF-β uses a novel mode of receptor activation to phosphorylate SMAD1/5 and induce epithelial-to-mesenchymal transition , 2018, eLife.

[34]  J. Crowley,et al.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[35]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[36]  Matthew D. Young,et al.  The driver landscape of sporadic chordoma , 2017, Nature Communications.

[37]  R. Derynck,et al.  Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis. , 2017, The Journal of clinical investigation.

[38]  T. Kornberg.  Distributing signaling proteins in space and time: the province of cytonemes. , 2017, Current opinion in genetics & development.

[39]  J. Horiguchi,et al.  Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients , 2017, International journal of oncology.

[40]  O. Bayrak,et al.  The molecular aspects of chordoma , 2016, Neurosurgical Review.

[41]  J. Blay,et al.  Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)† , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  S. Stacchiotti,et al.  Building a global consensus approach to chordoma: a position paper from the medical and patient community. , 2015, The Lancet. Oncology.

[43]  Cole Trapnell,et al.  Pseudo-temporal ordering of individual cells reveals dynamics and regulators of cell fate decisions , 2014, Nature Biotechnology.

[44]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[45]  Shuliang Song,et al.  Involvement of ubiquitin-conjugating enzyme E2C in proliferation and invasion of prostate carcinoma cells. , 2014, Oncology research.

[46]  C. Fletcher,et al.  WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition , 2014, Pathology.

[47]  J. Erler,et al.  Tumor-Secreted LOXL2 Activates Fibroblasts through FAK Signaling , 2013, Molecular Cancer Research.

[48]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[49]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[50]  B. Nahed,et al.  Chordoma: current concepts, management, and future directions. , 2012, The Lancet. Oncology.

[51]  J. Streilein,et al.  On the mechanisms by which transforming growth factor‐β2 alters antigen‐presenting abilities of macrophages on T cell activation , 1997, European journal of immunology.

[52]  R. Derynck,et al.  TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors , 1994, The Journal of cell biology.

[53]  R. Hendriks,et al.  A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. , 2018, Journal of autoimmunity.

[54]  A. Goldstein,et al.  Chordoma: incidence and survival patterns in the United States, 1973–1995 , 2004, Cancer Causes & Control.

[55]  C. Arteaga,et al.  Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. , 2003, Cancer research.

[56]  G. von Minckwitz,et al.  Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. , 1998, Laboratory investigation; a journal of technical methods and pathology.